Idarucizumab for Emergency Reversal of Anticoagulant Effects of Dabigatran: Interim Results of a Japanese Post-Marketing Surveillance Study

INTRODUCTION: Idarucizumab, a monoclonal antibody fragment, was developed to reverse the anticoagulant effect of dabigatran, and it was approved in Japan in September 2016. An all-case post-marketing surveillance is ongoing to collect data in Japanese patients treated with idarucizumab who had serio...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cardiol Ther
Hauptverfasser: Yasaka, Masahiro, Yokota, Hiroyuki, Suzuki, Michiyasu, Asakura, Hidesaku, Yamane, Teiichi, Ogi, Yukako, Ochiai, Kaori, Nakayama, Daisuke
Format: Artigo
Sprache:Inglês
Veröffentlicht: Springer Healthcare 2020
Schlagworte:
Original Research
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7237558/
https://ncbi.nlm.nih.gov/pubmed/32152956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40119-020-00165-8
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge